Abiopharma

CARDAX, INC. (CDXI)

Symbol	CDXI
Name	CARDAX, INC.
Sector	UNDEFINED
Region	North America
Industry	-
Address	96822 United States HI 2800 Woodlawn Drive Suite 129
Telephone	+1 808-457-1400
Fax	—
Email	—
Website	https://cardaxpharma.com
Incorporation	US
Incorporated On	2006
Employees	—
Fiscal Year	12/31
Public Since	—
Exchanges	OTC
Auditor	—
Audit Status	AUDITED
Reporting Status	Dark: Alternative Reporting Standard
CIK	0001544238
Description	Cardax is a consumer health company focused on marketing ZanthoSyn, a physician recommended astaxanthin dietary supplement for inflammatory health. The Company previously focused on development of pharmaceuticals for diseases driven by inflammation. The Company may seek to monetize CDX-101, the Companys pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Companys pre-clinical pharmaceutical candidate for macular degeneration. Additional info from OTC: Cardax is a consumer health company focused on marketing ZanthoSyn, a physician recommended astaxanthin dietary supplement for inflammatory health. The Company previously focused on development of pharmaceuticals for diseases driven by inflammation. The Company may seek to monetize CDX-101, the Companys pre-clinical pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, and CDX-301, the Companys pre-clinical pharmaceutical candidate for macular degeneration.

2024-11-08 17:00

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

2024-11-04 17:00

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

2024-08-28 02:42

Expert Market symbol attribute type Security_Name was changed. Previous value: -. New value: CARDAX INC.

2024-08-27 08:16

OTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: CARDAX INC.

2024-07-01 00:00

Air Products to Broadcast Fiscal Third Quarter Earnings Teleconference on August 1, 2024

2024-05-17 00:00

Air Products Declares Quarterly Dividend

2024-05-06 00:00

Air Products Announces Successful Performance Test of AP-DMR™ LNG Process Technology for Coral South FLNG Facility

2024-04-30 00:00

Air Products Reports Fiscal 2024 Second Quarter GAAP EPS of $2.57 and Adjusted EPS of $2.85

2024-04-23 00:00

Air Products Announces Plans to Build Network of Commercial-Scale Multi-Modal Hydrogen Refueling Stations Connecting Edmonton and Calgary, Alberta, Canada

2024-04-17 00:00

Air Products Again Earns Spot on Barron’s 100 Most Sustainable Companies List for the 6th Consecutive Year